- Home
- BTCT vs MRKR Comparison
BTCT vs MRKR Comparison
Compare BTCT & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTCT | MRKR |
|---|---|---|
| Founded | 2006 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 16.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BTCT | MRKR |
|---|---|---|
| Price | $1.74 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.17 |
| AVG Volume (30 Days) | 98.9K | ★ 336.9K |
| Earning Date | 05-04-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,427,000.00 | $4,694,988.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 83.61 | N/A |
| 52 Week Low | $1.57 | $0.81 |
| 52 Week High | $9.90 | $5.95 |
Technical Indicators
Market Signals| Indicator | BTCT | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 37.69 | 61.49 |
| Support Level | $1.82 | $1.40 |
| Resistance Level | $2.05 | $1.48 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 5.43 | 78.03 |
Price Performance
Historical ComparisonAbout BTCT BTC Digital Ltd.
BTC Digital Ltd is a crypto asset technology company based in the U.S. with a focus on bitcoin mining. The company also generates revenue through mining machine resale and rental business operations. Geographically, the financial assets of the company is located in the United States, Singapore, Hong Kong and the PRC.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.